HBV Collaborations & Partnerships

Our Partners






The Baruch S. Blumberg Institute (Blumberg) and Drexel University (Drexel)

In February 2014, we entered into an exclusive, worldwide, sub-licensable license agreement with Blumberg and Drexel for certain compounds that fall into one of three different compound series: cccDNA inhibitors, capsid assembly inhibitors and hepatocellular carcinoma, or HCC, inhibitors. A second license agreement was signed in November 2014 covering epigenetic modifiers of cccDNA and stimulator of interferon genes (STING) agonists.



Acquisition of Enantigen Therapeutics, Inc. (Enantigen)

In October 2014, we acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, we acquired our HBV surface antigen secretion inhibitor program and one of our capsid assembly inhibitor programs.





Research Collaboration and Funding Agreement with Blumberg

In October 2014, we entered into an exclusive research collaboration and funding agreement with Blumberg for three years, renewable for an additional three years. Research will be conducted in HBV and liver cancer. Under this agreement, we have the right to obtain an exclusive, royalty bearing, worldwide license to any of the intellectual property generated through the research collaboration, on predetermined terms. in June 2016, we entered into an amended and restated agreement to extend the initial term of the agreement to October 2018, with the option to extend for two additional one year terms. 




Saint Louis University Liver Center

In May 2016, we signed a licensing and research collaboration agreement with the Saint Louis University Liver Center to develop Ribonuclease H (RNaseH) inhibitors. RNaseH is a component of the viral polymerase and crucial to HBV replication. We believe that an RNaseH inhibitor could complement other direct antiviral HBV products by further crippling the viral replication process, which we believe is going to be a critical component in achieving a cure for chronic HBV. This collaboration allows us to further expand our pipeline and add another program focusing on a novel aspect of the HBV viral lifecycle.